Daily Endocrinology Research Analysis
Three impactful endocrinology-related studies stood out today: a phase 3 RCT showed dotinurad outperformed febuxostat in achieving target serum urate in gout; a multicenter RCT demonstrated that telemonitoring with connected devices significantly improved CGM time-in-range in insulin-treated type 2 diabetes; and a methodological study integrated liver deuterium metabolic imaging with plasma isotope dilution to model postprandial hepatic glucose kinetics after bariatric surgery.
Summary
Three impactful endocrinology-related studies stood out today: a phase 3 RCT showed dotinurad outperformed febuxostat in achieving target serum urate in gout; a multicenter RCT demonstrated that telemonitoring with connected devices significantly improved CGM time-in-range in insulin-treated type 2 diabetes; and a methodological study integrated liver deuterium metabolic imaging with plasma isotope dilution to model postprandial hepatic glucose kinetics after bariatric surgery.
Research Themes
- Digital health and telemonitoring in insulin-treated type 2 diabetes
- Urate-lowering therapy optimization with novel agents
- Advanced metabolic imaging and modeling of hepatic glucose kinetics post-bariatric surgery
Selected Articles
1. Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.
In a double-blind phase 3 RCT (n=441 FAS), dotinurad 4 mg/day achieved serum urate ≤6.0 mg/dL more frequently than febuxostat 40 mg/day at week 24 (73.6% vs 38.1%; adjusted difference 35.9%; P<0.0001). Dotinurad 2 mg/day was noninferior to febuxostat 40 mg/day at week 12, and adverse event rates were similar between groups.
Impact: This trial provides high-quality evidence that a selective urate reabsorption inhibitor can outperform xanthine oxidase inhibition at commonly used doses, informing guideline updates and therapeutic choices in gout.
Clinical Implications: Dotinurad 4 mg/day may be preferred over febuxostat 40 mg/day when the primary goal is achieving serum urate ≤6.0 mg/dL, with similar short-term safety; however, long-term flare and tophus outcomes remain to be established.
Key Findings
- At week 24, responder rate (serum urate ≤6.0 mg/dL) was higher with dotinurad 4 mg/day vs febuxostat 40 mg/day: 73.6% vs 38.1% (adjusted difference 35.9%; 95% CI 27.4%–44.4%; P<0.0001).
- At week 12, dotinurad 2 mg/day was noninferior to febuxostat 40 mg/day (55.5% vs 50.5%; adjusted difference 5.2%; 95% CI −3.7% to 14.2%).
- Treatment-emergent adverse event incidences were similar between groups.
Methodological Strengths
- Randomized, multicenter, double-blind, parallel-group phase 3 design with adequate sample size (n=451 randomized; n=441 FAS).
- Predefined superiority and noninferiority analyses with clinically meaningful primary endpoint.
Limitations
- 24-week duration focuses on biochemical target without long-term clinical outcomes (flares, tophi, renal/cardiovascular endpoints).
- Comparator dose limited to febuxostat 40 mg/day and a single-country (Chinese) cohort may affect generalizability.
Future Directions: Evaluate long-term clinical outcomes (flare rate, tophus resolution, renal/cardiometabolic effects), head-to-head comparisons with higher febuxostat doses and allopurinol, and outcomes in diverse populations.
OBJECTIVE: Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. METHODS: This phase 3, multicenter, randomized, double-blind, parallel-group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad or febuxostat. The primary end point was the responder rate (proportion of patients achieving serum urate levels ≤6.0 mg/dL) at week 24 in the full analysis set (FAS) to demonstrate superiority of dotinurad 4 mg/day to febuxostat 40 mg/day. The secondary end points included the responder rate at week 12 to show the noninferiority of dotinurad 2 mg/day to febuxostat 40 mg/day. Treatment-emergent adverse events (TEAEs) were also recorded. RESULTS: A total of 451 patients were randomized, and 441 were included in the FAS. Baseline characteristics were well balanced between treatment groups. The responder rate at week 24 was significantly higher for dotinurad 4 mg/day versus febuxostat 40 mg/day (73.6% vs 38.1%; adjusted difference 35.9% [95% confidence interval (CI) 27.4%-44.4%]; P < 0.0001), and at week 12, dotinurad 2 mg/day was noninferior to febuxostat 40 mg/day (55.5% vs 50.5%; adjusted difference 5.2% [95% CI -3.7% to 14.2%]). Incidences of TEAEs in the dotinurad and febuxostat groups were similar. CONCLUSION: Dotinurad 4 mg/day was superior to febuxostat 40 mg/day in achieving serum urate levels ≤6.0 mg/dL at week 24 and was well tolerated in Chinese patients with gout.
2. Effectiveness and safety of telemonitoring compared with standard of care in people with type 2 diabetes treated with insulin: a national multicenter randomized controlled trial.
In a national multicenter RCT (n=331), a comprehensive telemonitoring intervention (CGM, connected insulin pens, activity tracker, apps, and proactive clinician follow-up) improved CGM time-in-range versus standard care over 3 months (estimated treatment difference 13.6%, p=0.004).
Impact: Demonstrates robust, short-term glycemic benefits of integrated telemonitoring in insulin-treated T2D, supporting scalable digital-health models that align with modern diabetes care.
Clinical Implications: Health systems can consider deploying integrated telemonitoring programs to improve TIR in insulin-treated T2D, recognizing resource needs and the importance of proactive clinical engagement.
Key Findings
- Telemonitoring improved CGM time-in-range compared with standard care over 3 months (estimated treatment difference 13.6%; 95% CI 7.2–20.0; p=0.004).
- Intervention combined CGM, connected insulin pens, an activity tracker, smartphone apps, and repeated clinician-initiated phone contacts.
- Observed treatment difference in TIR change was 6.8% (95% CI 4.8–8.8) favoring telemonitoring.
Methodological Strengths
- Multicenter randomized design with objective CGM-based primary endpoint.
- Comprehensive, protocolized digital intervention reflecting real-world scalable components.
Limitations
- Open-label design and short 3-month follow-up limit assessment of durability and potential bias.
- Resource-intensive intervention may challenge implementation and generalizability across settings.
Future Directions: Assess durability, cost-effectiveness, and effects on hypoglycemia, hospitalizations, and quality of life over longer periods; define minimal effective telemonitoring components.
BACKGROUND: Telemonitoring interventions facilitating adjustments in medication may improve glycemic control more effectively. Hence, the aim of this randomized controlled trial was to explore the effectiveness and safety of telemonitoring compared with standard of care in people with type 2 diabetes (T2D) on insulin therapy. METHODS: The trial was a Danish multicenter open-label randomized controlled trial with a threemonth trial period. People with T2D on insulin therapy were randomized (1:1) to telemonitoring (intervention) or standard of care (control) based on the EASD/ADA consensus report. The telemonitoring group used a continuous glucose monitor (CGM), a connected insulin pen, an activity tracker, and smartphone applications throughout the trial period. Hospital staff monitored the telemonitoring groups' data and contacted the participants by telephone repeatedly. The primary endpoint was change from baseline in CGM time in range (3·9-10·0 mmol/L) three months after randomization. An analysis of covariance was used to assess the difference in change from baseline between the telemonitoring and standard of care group. FINDINGS: In total, 331 participants were included and randomized (telemonitoring: 166; standard of care: 165). The observed treatment difference in change from baseline in CGM-TIR was 6·8 % (CI: 4·8, 8·8), and the estimated treatment difference was 13·6 % (CI: 7·2, 20·0) (p = 0·004) in favor of telemonitoring. INTERPRETATION: The trial demonstrated that telemonitoring is superior to standard of care in T2D for improving glycemic control. FUNDING: The trial was supported by The Innovation Fund Denmark, Novo Nordisk A/S, and Dexcom, Inc.
3. Modeling hepatic glucose tracer kinetics from isotope dilution technique and deuterium metabolic imaging in postbariatric surgery and nonoperated individuals.
The authors developed a postprandial hepatic glucose kinetics model by integrating liver deuterium metabolic imaging with plasma isotope dilution in humans. Applying this framework to 10 RYGB patients and 10 healthy controls during a labeled OGTT demonstrates a path toward organ-level quantification of hepatic glucose handling.
Impact: Introduces an innovative organ-level modeling approach that combines imaging and tracer kinetics, enabling mechanistic insights into hepatic glucose handling after bariatric surgery.
Clinical Implications: While primarily methodological, this framework could inform future assessments of hepatic insulin sensitivity and guide therapeutic strategies post-bariatric surgery.
Key Findings
- Proposed a mathematical model of postprandial hepatic glucose kinetics that integrates liver deuterium metabolic imaging with plasma isotope dilution data.
- Applied the model to human datasets from 10 Roux-en-Y gastric bypass (RYGB) patients and 10 healthy controls during a labeled OGTT (60 g), enabling organ-level analysis.
- Demonstrated feasibility of combining imaging-derived hepatic signals with systemic tracer kinetics to characterize hepatic glucose handling.
Methodological Strengths
- Innovative integration of organ-level imaging (DMI) with plasma tracer kinetics in humans.
- Application across two distinct cohorts (post-RYGB and healthy controls) to test the framework.
Limitations
- Small sample size (n=20) limits generalizability and statistical inference.
- Abstract does not report specific quantitative outcomes; model validation against independent datasets and gold standards is needed.
Future Directions: Validate the model in larger and diverse cohorts, quantify hepatic flux components, and evaluate sensitivity to therapeutic interventions (e.g., GLP-1RA, SGLT2i) and disease states (NAFLD/MASLD).
Despite extensive research on liver metabolism, mathematical models describing hepatic glucose kinetics are currently limited due to the lack of organ-level data. Here, we propose a model of postprandial hepatic glucose kinetics exploiting liver deuterium metabolic imaging (DMI) data combined with plasma isotope dilution analysis in humans. We used data from 10 individuals who had previously undergone Roux-en-Y gastric bypass surgery (RYGB) and 10 healthy controls (HCs). The experimental setting included a labeled oral glucose tolerance test comprising 60 g of [6,6'-